To date, monoclonal antibodies (mAbs) targeting either PD1 (e.g., nivolumab, pembrolizumab, cemiplimab) or PD-L1 (e.g., atezolizumab, durvalumab, avelumab) have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of different cancers [2]. This evidence concerns the gene PDCD1 and cancer.